Pregnancy‑specific terminology

Antenatal care
Structured assessments, screening and support offered during pregnancy, shaped by national guidance and local pathways.

Antenatal red flags
Symptoms or findings requiring urgent assessment, such as reduced fetal movements, severe headache with visual disturbance, or abdominal pain with bleeding.

Fetal growth restriction
A pattern where the baby does not grow as expected. Often linked to placental conditions, maternal health factors or delays in ultrasound access.

Perinatal period
Pregnancy and the weeks after birth. Some analyses use a wider timeframe to capture later‑presenting conditions.

Postnatal morbidities
Health conditions emerging after birth, including infection, hypertension, thrombosis, mental health concerns and wound complications.

Uterine rupture
A rare obstetric emergency associated with scar tissue, obstructed labour or inappropriate uterotonic use. Early recognition and escalation are essential.

Vaginal birth after caesarean (VBAC)
Planned vaginal birth for someone with a previous caesarean. Requires clear risk discussion and access to timely support.

Gynaecology‑specific terminology

Adenomyosis
Tissue similar to the womb lining growing within the uterine muscle. Can cause pain and heavy bleeding, often diagnosed late.

Chronic pelvic pain
Pain lasting six months or more with a wide range of potential causes. Waiting times and access to multidisciplinary support vary across the NHS.

Endometrial hyperplasia
Thickening of the womb lining. Certain patterns carry a higher cancer risk and therefore influence monitoring and treatment.

Endometriosis
A chronic inflammatory condition where tissue similar to the womb lining grows outside the uterus. Often associated with diagnostic delay.

Fibroids (leiomyomas)
Benign growths of the uterus. May cause heavy bleeding, pain or fertility issues; treatment access varies regionally.

Ovarian torsion
Twisting of the ovary and its blood supply. Requires urgent assessment to reduce the risk of tissue damage.

Premature ovarian insufficiency
Reduced ovarian function before age 40. Can affect bone health, cardiovascular risk and fertility.

Medication‑safety terminology

Contraindication
A reason why a medicine should not be used because the likely harm outweighs benefit.

Drug interactions
Situations where medicines influence each other’s effects. Electronic systems vary in how reliably they detect interactions.

High‑risk medicines
Medicines with a higher potential for serious harm if used incorrectly, such as anticoagulants, insulin and certain antiepileptics.

Off‑label use
Use of a licensed medicine outside its approved indications. Common in pregnancy because evidence may be limited, requiring clear risk communication.

Pharmacovigilance
Processes to detect, assess and prevent medicine‑related harm, including safety alerts and reporting systems.

Teratogenicity
The potential for a substance to cause congenital anomalies. Evidence quality differs across medicines.

Therapeutic monitoring
Planned measurement of blood levels or relevant tests to maintain safety and effectiveness. Particularly relevant where pregnancy alters drug metabolism.

NHS‑systems terminology

Care bundle
A small set of evidence‑based actions designed to be delivered consistently. Used in maternity to target hypertension, fetal monitoring and postpartum haemorrhage.

Clinical governance
The organisational framework for ensuring safe, high‑quality care. Includes audit, training, supervision and incident investigation.

Digital interoperability
The ability of NHS systems to exchange information reliably. Fragmentation can affect recognition of deterioration or medication conflicts.

Escalation policy
A documented route for raising concern when a patient’s condition changes or expected improvement does not occur.

Integrated care system (ICS)
A regional partnership responsible for planning services across NHS organisations and local authorities.

Local Maternity and Neonatal System (LMNS)
The regional structure coordinating maternity improvement programmes, monitoring outcomes and supporting service design.

Maternity Incentive Scheme (CNST)
A national programme linking certain safety actions to financial incentives to encourage consistent implementation of good practice.

Patient safety incident response framework (PSIRF)
The national approach to incident learning, emphasising systems‑based analysis.

Sentinel event
A serious, often rare event indicating an urgent need for review.

Royal Colleges, NICE and regulators

NICE guidelines
Evidence‑based recommendations covering diagnosis, management and service organisation.

NICE quality standards
Short statements reflecting priority areas for improvement.

Royal College of Obstetricians and Gynaecologists (RCOG)
Produces clinical guidelines, develops standards and contributes to national improvement work.

Royal College of Midwives (RCM)
Represents midwives and contributes to education, policy and workforce planning.

Royal College of General Practitioners (RCGP)
Supports primary care clinicians, including those managing menstrual and early pregnancy conditions.

Royal College of Paediatrics and Child Health (RCPCH)
Covers neonatal care standards and early infant health guidance.

Royal College of Radiologists (RCR)
Sets standards for imaging, including radiation safety in pregnancy.

Royal College of Emergency Medicine (RCEM)
Provides guidance relevant to gynaecological and early pregnancy emergencies.

Royal Pharmaceutical Society (RPS)
Develops professional standards relevant to medicines safety.

HSSIB
Investigates patient safety events to identify system‑level learning.

MHRA
Regulates medicines and medical devices and issues safety alerts.

NIHR terminology

National Institute for Health and Care Research (NIHR)
The main public funder of health and care research in the UK.

NIHR Evidence
Plain‑language summaries of research findings for practitioners and the public.

Applied research collaborations (ARCs)
Partnerships translating research into practice, including work on maternity outcomes and inequalities.

Health technology assessment (HTA)
Evaluation of clinical and cost‑effectiveness to support decision‑making.

Research gaps
Areas where evidence is weak or limited, such as medicines in pregnancy and chronic pelvic pain.

Trial inclusivity
How representative study populations are of the people who use services.

Stillbirth, neonatal death and perinatal mortality

Stillbirth
The death of a baby before or during birth from 24 completed weeks of pregnancy onwards.

Late fetal loss
Pregnancy loss before 24 weeks, not included in national stillbirth statistics.

Intrapartum stillbirth
A stillbirth occurring during labour. Often examined closely in safety reviews.

Neonatal death
The death of a liveborn baby within the first 28 days of life.

Perinatal mortality rate
Combined measure of stillbirths and neonatal deaths, used to assess safety and equity.

Unexpected deterioration
A sudden or progressive change in a baby’s condition that was not anticipated. Often highlighted in investigations.

Classification systems
Frameworks for categorising causes of perinatal death. Variation between systems affects comparability.

Placental pathology
Examination of the placenta to identify potential causes of fetal or neonatal death.

MBRRACE‑UK terminology

MBRRACE‑UK
The national collaboration responsible for surveillance of perinatal mortality and confidential enquiries into maternal deaths.

Confidential enquiry
An anonymised review of selected cases to identify system learning.

Surveillance report
Annual national statistics on stillbirths and neonatal deaths, including trends and inequalities.

Thematic learning
Patterns emerging across cases, often involving delayed recognition, communication issues or gaps in monitoring.

Inequalities analysis
Detailed review of outcomes by deprivation, ethnicity and geography.

Case selection
Criteria determining which cases undergo detailed review.

Enquiry recommendations
National system‑level recommendations directed at NHS organisations and professional bodies.

Drug glossary

(class‑level only)

Antiepileptic medicines

A broad group used to manage seizure disorders. Systems issues often relate to communication across specialties, interactions with hormonal contraception, and the need for reliable digital alerts for pregnancy exposures.

Anticoagulants

Medicines that reduce blood clotting. Frequently appear in surveillance and investigations because of transitions of care, monitoring requirements and potential interactions with other medicines.

Antidepressants

Covers several classes with different mechanisms. Systems themes include fragmented prescribing, variable access to specialist review and differing digital prompts about pregnancy or breastfeeding.

Antihypertensive medicines

Used to manage raised blood pressure. National programmes frequently highlight early recognition of hypertension, monitoring and escalation rather than specific drug effects.

Antipsychotics

A group used in the management of severe mental health conditions. Systems considerations include continuity between perinatal mental health teams, primary care and maternity services.

Corticosteroids

Medicines that reduce inflammation. In maternity settings, they are also used for fetal lung development, which requires coordinated timing across teams.

Diuretics

Medicines that increase urine output. In system reviews, they appear mainly in relation to diagnostic overshadowing where symptoms in pregnancy are attributed to normal physiological changes rather than monitored conditions.

Hormonal contraceptives

Includes combined hormonal methods, progestogen‑only methods and long‑acting reversible contraceptives. System themes involve access barriers, digital documentation and missed opportunities for informed choice.

Hormone replacement therapies

Used to manage menopausal symptoms. Appear in system discussions around access, variation in prescribing, and differing levels of clinician training.

Insulins

Medicines used to manage blood glucose. System factors include glucose monitoring, communication between specialist teams and the reliability of digital prescribing tools.

Magnesium preparations

Used in specific obstetric contexts. Appear in investigations where competing priorities, staff unfamiliarity or unclear escalation pathways affect delivery.

Non‑steroidal anti‑inflammatory drugs

A broad group used for pain relief. System themes relate to over‑the‑counter availability, fragmented documentation and interactions with existing medical conditions.

Opioids

Medicines used to relieve moderate or severe pain. System themes include monitoring, the risk of escalation without review and challenges at discharge.

Oral contraceptives

Tablets containing oestrogen and progestogen or progestogen alone. System issues often relate to record‑keeping, contraindication alerts and managing missed pills.

Progestogens

Hormonal medicines used across several women’s health pathways. Appear in system‑level reviews about variation in access and differing interpretations of guidance.

Thyroid medicines

Medicines used to manage underactive or overactive thyroid conditions. Appear in system analysis relating to monitoring, test interpretation and transitions between primary and specialist care.

Uterotonics

Medicines that act on the uterus, commonly referenced in the context of labour and postpartum haemorrhage care bundles. System factors include storage, availability and staff familiarity.